

Binary-QSAR guided virtual screening of FDA approved drugs and compounds in clinical investigation against SARS-CoV-2 main protease

Lalehan OKTAY¹, Ece ERDEMOĞLU^{1,2}, İlayda TOLU¹, Yeşim YUMAK^{1,3}, Ayşenur ÖZCAN^{1,4}, Elif ACAR^{1,4}, Şehriban BÜYÜKKILIÇ^{1,5}, Alpsu OLCAN^{1,6}, Serdar DURDAĞI^{1,*}

¹Computational Biology and Molecular Simulations Laboratory, Department of Biophysics, School of Medicine, Bahçeşehir University, İstanbul, Turkey

²School of Medicine, Mersin University, Mersin, Turkey

³Faculty of Science and Letters, Tokat Gaziosmanpaşa University, Tokat, Turkey

⁴Faculty of Medicine, İstanbul Medeniyet University, İstanbul, Turkey

⁵Faculty of Science, Necmettin Erbakan University, Konya, Turkey

⁶School of Medicine, Bahçeşehir University, İstanbul, Turkey

Received: 28.06.2021

Accepted/Published Online: 06.08.2021

Final Version: 30.08.2021

Abstract: With the emergence of the new SARS-CoV-2 virus, drug repurposing studies have gained substantial importance. Combined with the efficacy of recent improvements in ligand- and target-based virtual screening approaches, virtual screening has become faster and more productive than ever. In the current study, an FDA library of approved drugs and compounds under clinical investigation were screened for their antiviral activity using the antiviral therapeutic activity binary QSAR model of the MetaCore/MetaDrug platform. Among 6733-compound collection, we found 370 compounds with a normalized therapeutic activity value greater than a cutoff of 0.75. Only these selected compounds were used for molecular docking studies against the SARS-CoV-2 main protease (M^{pro}). After initial short (10 ns) molecular dynamics (MD) simulations with the top-50 docking scored compounds and following molecular mechanics generalized born surface area (MM/GBSA) calculations, top-10 compounds were subjected to longer (100 ns) MD simulations and end-point MM/GBSA estimations. Our virtual screening protocol yielded Cefuroxime pivoxetil, an ester prodrug of second-generation cephalosporin antibiotic Cefuroxime, as being a considerable molecule for drug repurposing against the SARS-CoV-2 M^{pro}.

Key words: Binary QSAR, virtual screening, drug repurposing, SARS-CoV-2

1. Introduction

In December 2019, a local outbreak of pneumonia with unknown origin was reported in Wuhan (Hubei, China), and a novel coronavirus was soon found to be the underlying cause (Dong et al., 2020). It has quickly become a global pandemic and has spread to other countries, affecting around 200 million people worldwide (WHO, 2021). Consequently, it has now become the biggest public health emergency all around the world. Shortly after the World Health Organization (WHO) denominated the disease as coronavirus disease 2019 or COVID-19 (Ghosh et al., 2020). The International Committee on Taxonomy of Viruses defined the virus as SARS-CoV-2 (Wu et al., 2020). The severity of the disease ranges from asymptomatic cases to multiorgan failure deaths. Although most of the patients experience some mild prodromal symptoms 5 days after the incubation period, such as fever, fatigue, cough and shortness of breath, in some cases, the

cytokine storm following the acute respiratory distress syndrome induces septic shock, pulmonary embolism and multiorgan failure associated with an increased risk of death (Ruano-Gallego et al., 2021). Some studies claim the incidence of deep venous thrombosis and pulmonary embolism in hospitalized COVID-19 patients is 25% to 58% (Erben et al., 2021). Potere et al. reported the serious statement of the disease that mortality rate is high in critically ill patients. (Potere et al., 2020). This disease with its wide clinical spectrum has suddenly become more than a global healthcare problem with its economic and social consequences. These consequences alarmed the world to find an urgent treatment. Unfortunately, there is currently no globally accepted medicine for COVID-19 despite a great number of research (Han et al., 2021).

SARS CoV-2 is a single stranded positive-sense RNA virus that is a member of the β -coronaviruses family

* Correspondence: serdar.durdagi@med.bau.edu.tr

(Kirtipal et al., 2020). SARS-CoV-2 contains approximately 30,000 nucleotide RNA sequences responsible for encoding the entire viral proteome. The viral genome is divided into a nonstructural protein (NSP) coding region, a helper protein coding region and a structural protein coding region (Kirtipal et al., 2020). Furthermore, multiple open reading frames (ORF) are present. Structural proteins such as spike (S), membrane (M), envelope (E), and nucleocapsid (N) proteins are produced from the ORF's close to the 3'-terminus of the genome and also nonstructural proteins such as the main protease is encoded in the 5'-terminus region (Chen et al., 2020).

The main protease (M^{pro}) or 3CLpro (also called chymotrypsin-like protease or Nsp5) enzyme is the pivotal point of drug discovery research for COVID-19. The enzyme plays an important role in the processing of polyproteins translated from the viral RNA and their separation into different functional components. The inactivation of this enzyme blocks processes such as viral replication and transcription, stopping the virus from reproducing in the host (Ahmed et al., 2021; Molavi et al., 2021). The most important assignment of the M^{pro} is to cleave pp1a and pp1ab, replicase 1a and replicase 1ab, respectively. The pp1a and pp1ab are the polyproteins of SARS CoV-2 resulting from the codification of the ORFs, ORF1a and ORF1b. Coding these ORFs is crucial for the virus to form its structural and nonstructural proteins. After the production of these polyproteins, the M^{pro} takes the scene and starts to cleave these polyproteins at 11 sites with papain-like protease to create the functional proteins of SARS CoV-2 (Shitrit et al., 2020; Guedes et al., 2021).

M^{pro} is a homodimeric proteolytic enzyme which is crucial for the life cycle of SARS CoV-2. While M^{pro} monomers are enzymatically inactive when separated from each other, they become active in dimeric structure (Silvestrini et al., 2021). Histidine at the 41st position and Cysteine at the 145th position of the M^{pro} constitute the catalytic domain of the enzyme for the binding of substrates (Shitrit et al., 2020). Targeting the M^{pro} responsible for the virus-induced apoptotic signal is the most favorable option in inhibiting viral replication and dysregulation of signaling cascades in infected cells (Han et al., 2021; Rothan and Teoh, 2021).

In most studies on the catalytic activity of cysteine protease (Nsp5), it has been reported that it mainly depends on the interaction between Glu166 and Ser1 amino acids, and the proximity of the two protomers' S1 subpocket and N-terminal residues, thus their connection with dimer structures (Behnam, 2021).

Targeting the SARS CoV-2 M^{pro} may be a safer option, since this protease has a cleavage site which has no similarity with any human proteases and is special from the

standpoint of its recognition sequence Leu-Gln (Ser, Ala, Gly) on polyprotein 1ab (Zhang et al., 2020). Additionally, the proposed drugs that are identified/developed against the M^{pro} have a very low risk of mutation-mediated drug resistance. The M^{pro} sequence is protected amongst CoV's because M^{pro} mutations are highly mortal for the virus (Silvestrini et al., 2021). When we consider all of these features of SARS CoV-2 M^{pro} such as (i) its key role in the viral cycle, (ii) its targetable active zone in terms of both its perishable dimer structure and blockable catalytic dyad, (iii) its resistance against mutations, and (iv) specific recognition site, a drug aiming M^{pro} can be a convenient and secure option to tackle the SARS-CoV-2 virus.

Currently, in silico studies with computational simulations are the first step for developing a new drug, since this kind of virtual screening approaches make it possible to scan huge databases in a very short time at a very low cost for a chosen target. (Durdagi et al., 2020; Durdağı 2020; Tutumlu et al., 2020; Kanan et al., 2021). With the advantage of innovative in silico drug-discovery techniques, it is possible to integrate and mine a wide variety of high-throughput biological data developed globally for drug repurposing, to find new indications for existing drugs (Akhoon et al., 2019). The use of existing drugs which have already been approved to treat different diseases is another advantage of drug repurposing since they have already been studied in vivo and completed clinical trials. Therefore, their use in pandemics such as the COVID-19 is more suitable than new molecules that have never been tested.

In the current study, a binary QSAR model-guided virtual screening of FDA approved compounds and compounds in clinical investigation library which includes around 7000 compounds are performed.

2. Methods

2.1. Ligand Preparation

A total of 7922 ligands were downloaded from NPC library.¹ In order to avoid misleading results and decrease the nonspecificity, some filtration criteria on library is conducted: (i) Compounds that have molecular weight between 100 and 1000 g/mol are considered; (ii) compounds that have more than 100 rotatable bonds are not considered; (iii) compounds that have more than 10 hydrogen bond donor and acceptor are not considered. Thus, the total number of molecules were decreased to 6654 before the docking simulations. These compounds were prepared with LigPrep module (LigPrep, Schrodinger v.2017, New York, NY, USA) of Maestro molecular modeling package. After the ligand preparation total number of compounds was 6733.

¹NPC Library (2021). Website <https://tripod.nih.gov/npc>

2.2. Protein preparation

Crystal structure of SARS-CoV-2 main protease was downloaded from the Protein Data Bank with ID of 7CWC. The structure in apo form was prepared using the Protein Preparation tool in the Maestro molecular modeling suite. Initially, hydrogens were added, side chains and loops were mended, and disulfide bonds were created. Protonation states of the residues at physiological pH (7.4) were assigned using PROPKA. Conformational optimization was performed via the OPLS3e forcefield. Homodimer stoichiometry was kept for all molecular simulations.

2.3. Binary QSAR model

Our prefiltered ligand library was subjected to the antiviral therapeutic activity binary QSAR model in the MetaCore/MetaDrug platform from Clarivate Analytics. The MetaCore/MetaDrug platform uses QSAR predictions for pharmacokinetic and pharmacodynamic characterization of small molecules (Dogan and Durdagi, 2020). Viral binary QSAR model is used for the therapeutic activity predictions of the screened compounds [model description: training set, $N = 206$; test set, $N = 35$; sensitivity = 0.92; specificity = 0.95; accuracy = 0.94; Matthews correlation coefficient (MCC) = 0.88]. In the therapeutic activity prediction by the Viral binary QSAR model, predicted activity values are normalized between 0 and 1 (a value of more than 0.5 may be interpreted as potential therapeutic activity). Here, we used a higher cutoff (0.75). There were 370 compounds among screened library.

2.4. Molecular docking

Molecular docking simulations were performed on the surviving 370 compounds from binary QSAR screen using the Glide/SP docking algorithm. Crucial residues at the catalytic site of the M^{pro} such as His41, Cys145, and Glu166 were used to define the grid box. The thiol and hydroxyl groups of the residues enclosed in this box were allowed to rotate. Glide offers an optimization where van der Waals radii can be scaled for softening potentials of nonpolar parts of the ligands. Scaling factor was selected as 0.80 Å for ligand atoms having less than 0.15 partial charge. Flexible ligand sampling was used. Postdocking minimizations were also performed as part of Glide's docking algorithm.

2.5. Molecular dynamics simulations

Molecular dynamics (MD) simulations are used to explore the structural and dynamical features once the compounds bind to the infamous binding pocket of the main protease. The Desmond program was used for this purpose. Best scoring docked complexes were initially submerged in an orthorhombic water box of TIP3P water models and ions for neutralization. Salt concentration of 0.15 M was defined to the water box. As for all the previous experiments

conducted, OPLS3e forcefield was employed for assigning parameters. NPT ensemble was used and controlled by the Martyna–Tobias–Klein barostat and Nosé–Hoover thermostat, respectively. RESPA integrator is used with 2 fs time steps. Simulations are conducted at 310 K and 1 bar. Two different length of MD simulations are conducted: (i) short MD simulations (10 ns); (ii) long MD simulations (100 ns). While 100 trajectory frames are collected throughout the simulations in short MD simulations, 1000 frames are collected in long MD simulations.

2.6. Molecular mechanics generalized Born surface area (MM/GBSA) calculations

The MM/GBSA was used for calculating the binding free energies of the selected hits. Hou et al. reported that rescoring by MM/GBSA is an effective procedure to improve the predictions of docking methods (Hou et al., 2011). For this aim, MM/GBSA approach was preferred in this study (Miller et al., 2012). Average binding free energies of screened compounds were studied with MM/GBSA method. The OPLS3e force field for molecular mechanical energy and the surface-generalized Born model for polar solvation energy (VSGB), as well as the nonpolar solvation factor (G_{SA}), were used to calculate the endpoint energy. A total of 100 frames throughout the simulations are extracted, then MM/GBSA was calculated for the complexes. An average calculation of all the frames was considered.

3. Results and discussion

Considering the off-target binding, high costs, and slow pace of new drug discovery and development, drug repurposing – also known as drug repositioning – has become a more appealing method with the coronavirus pandemic, since it involves the use of relatively safe compounds, which could result in lower overall costs and faster maturation timelines, which is crucial for mass pandemics, like SARS-CoV-2. Our study aims to screen FDA approved drugs and compounds in clinical trials for antiviral activity and use these filtered compounds against the SARS-CoV-2 M^{pro} target.

Among the 6733 compounds, 370 compounds had normalized therapeutic activity prediction value of 0.75 or higher (Table S1). A histogram of the therapeutic activity prediction of the 6733-compound library revealed that the normalized predicted activity was mostly between 0.4 and 0.6 (Figure 1). The 370 identified compounds based on used QSAR model were used in the docking simulations.

Previously reported crucial residues, His41, Cys145 and Glu166 (Yoshino et al., 2020) were used to define the grid-box. The thiol and hydroxyl groups of the residues enclosed in this box were allowed to rotate. The Glide/SP docking score ranged between -7.60 kcal/mol to

–2.66 kcal/mol (Figure S1). Docking scores of identified 370 compounds are reported in Table S1. The best docking score was obtained from compound Cefuroxime axetil, which is the ester prodrug of second-generation cephalosporin antibiotic Cefuroxime. The 3rd best scoring compound, Cefuroxime pivoxetil is also an ester prodrug of Cefuroxime (Scott et al., 2001).

Top-50 high docking scored compounds (Table 1) were used in short (10 ns) MD simulations. Figures S2 shows the protein backbone atoms RMSD versus time plot of the selected top-10 compounds throughout 100 ns. In Figure S3, Lig fit Prot RMSD versus time plot for the same top-10 molecules is given. The RMSD of a ligand is displayed in Lig fit Prot when the protein-ligand complex is first fitted on the protein backbone and the RMSD of the ligand heavy atoms is calculated. Among the top-10 hit compounds, Ibutamoren showed the lowest Lig fit Prot RMSD, while Cilostamide has the most deviation. Cilostamide shows high deviation because it loses its initial contact with Thr24 and Thr25, instead to make interaction with Glu166 and Pro168 for last half of the 100 ns MD simulation (see Figure S7).

Average MM/GBSA scores of these 50 hit compounds are sorted and top-10 compounds were used in long (100 ns) MD simulations (Table 2). MM/GBSA analysis of the trajectories for 10 ns indicates Ibutamoren as being the ideal binder. However, for a 100 ns trajectory energy analysis, Cefuroxime pivoxetil, shows better average free energy of binding than the other compounds as it can be seen in the Box and Whisker plots of the MM/GBSA scores for the top-10 compounds in Figure 2. Given that Cefuroxime pivoxetil has one of the top docking scores, this compound may yield promising results. Extending MD simulations to 100 ns has given further insight into the

changing binding energies and further fortified the results. Figure 3 shows 2-dimensional and 3-dimensional ligand interaction diagrams of Cefuroxime pivoxetil. Crucial residues were found as His41, His164, Glu166, Gln189, and Gln192. 2-dimensional and 3-dimensional interaction diagrams of the remaining top-10 compounds are given in the supplementary materials (Figures S4–S12). Glu166 residue was crucial for ligand binding in Ibutamoren, which is selective ghrelin receptor and a growth hormone secretagogue agonist, and this interaction is sustained throughout the simulations (Figure S4). Corresponding residues were His41, Glu166, Asp187, and Gln189 in Ateviridine which is studied in the treatment of HIV (Figure S5). Figure S6 shows binding mode of another identified hit compound Ambamustine an antineoplastic agent. A selective PDE3 inhibitor Cilostamide showed a dramatic conformational change during the simulations. Its interactions with Thr24 and Thr25 break off and new contacts are established with Glu166, and Gln189 (Figure S7). Among the identified hit, Tafenoquine, which is an antimalaria drug (Haston et al., 2019) forms residue interactions mainly from Ser46, Glu166, and Gln189 (Figure S8). Montirelin is a thyrotropin releasing hormone analog (Sugimoto et al., 1996) constructs crucial interactions with Thr26, Cys44, and Glu166 (Figure S9). Ritonavir was also found as hit compound among identified molecules. Its interactions mainly form from Thr26, Ser46, Tyr118, and Glu166 (Figure S10). Corresponding main contacts were from Met49, Asn142, Gly143, Glu166, and Gln189 for Amlodipine which is calcium channel blocker (Figure S11). The importance of hydrogen bonding in ligand binding cannot be overstated. Because of their considerable influence on drug selectivity, metabolism, and adsorption, hydrogen-bonding properties should be




Figure 1. Histogram of therapeutic activity predictions from the MetaCore/ MetaDrug antiviral QSAR model for all 6733 compounds.

Table 1. Docking scores of top-10 compounds at the M^{pro} binding site. These compounds were initially used in short (10-ns) MD simulations. Table also shows average MM/GBSA scores of these compounds from derived 100-trajectories throughout the simulations. Prediction of antiviral therapeutic activity for the selected hit molecules using MetaCore/MetaDrug was also reported in the table. Values in parenthesis – Tanimoto prioritization (TP) – indicates similarity of the analyzed structure to the most similar compound in the training set.

Compound name	Glide/SP docking score (kcal/mol)	Antiviral (TP)	10 ns		100 ns	
			MM/GBSA (kcal/mol)	SD	MM/GBSA (kcal/mol)	SD
Ibutamoren	-7.27	0.85 (49.84)	-80.07	7.34	-59.77	12.75
Cefuroxime pivoxetil	-7.42	0.79 (33.60)	-74.63	7.88	-75.08	7.31
Cefuroxime axetil	-7.60	0.79 (33.27)	-63.80	5.62	-58.40	7.15
Ambamustine	-7.23	0.79 (58.30)	-61.89	9.00	-69.17	11.52
Montirelin	-7.47	0.75 (54.38)	-59.39	3.60	-49.88	6.36
Atevirdine	-6.35	0.75 (100.00)	-58.09	4.82	-56.93	5.99
Ritonavir	-6.37	0.79 (100.00)	-54.38	11.18	-51.97	9.37
Cilostamidum	-6.45	0.77 (39.83)	-53.68	4.80	-52.13	4.76
Amlodipine	-6.60	0.78 (34.10)	-53.63	4.63	-43.80	10.42
Tafenoquine	-6.66	0.83 (40.28)	-53.40	4.98	-49.60	6.73




Figure 2. MM/GBSA score Box and Whisker plots for the selected top-10 compounds. MM/GBSA scores of 100 frames extracted from 100 ns simulations trajectories was considered.

considered in drug design. Compounds Ambamustine, Cefuroxime axetil, Cefuroxime pivoxetil and Atevirdine maintain hydrogen bonding interactions with Gln189 throughout the 100 ns MD simulations (Figure 3, and Supplementary Figures S5, S6, S12).

In geriatric patients admitted with SARS-CoV-2 infection, amlodipine, which is a dihydropyridine calcium channel blocker, was found to be related with

significantly lower mortality and a lower probability of intubation and mechanical breathing (Solaimanzadeh 2020). Atevirdine, as the name implies, acts as an antiviral agent by inhibiting nonnucleoside reverse transcriptase (Reichman et al., 1995). Construction of hydrogen bonds with crucial residue Glu166 at the SARS-CoV-2 M^{pro} and compounds Ambamustine, Amlodipine, Cefuroxime pivoxetil, Cefuroxime axetil, Ibutamoren, Montirelin




Figure 3. (A) 3D representation of the Cefuroxime pivoxetil at binding site. The average frame from 100 ns trajectory was used. (B) 2D interaction diagram of Cefuroxime pivoxetil at M^{pro} binding site with residues around 3 Angstrom. (C) Time-dependent protein-ligand contact panel throughout 100 ns simulation. Top-panel shows total contacts, while bottom-panel shows formed/broken interaction between the protein and ligand.

and Ritonavir must be also highlighted (Figures S2–S11). Notably, Ibutamoren, an agonist of the growth hormone secretagogue receptor, has also been reported as having antiviral activity against Ebola virus-like particles (Yoon et al., 2020). Treatment with Ritonavir or Ritonavir in combination with Lopinavir against hospitalized SARS-CoV-2 patients, however, resulted in no significant effect in clinical improvement, mortality rates or decrease in SARS-CoV-2 viral RNA levels (Dalerba et al., 2020; Horby et al., 2020). Furthermore, hydrophobic interactions were assembled between His41 and Ateveridine and between Tyr118 and Montirelin.

4. Conclusion

The reported study focuses on the binary QSAR screening of the FDA library of approved and under clinical investigation

compounds for potential antiviral drug candidates against the SARS-CoV-2 main protease by drug repurposing. Initial filtering of potential antiviral compounds using the therapeutic activity binary QSAR models available in the MetaCore/MetaDrug platform aimed to pick only use molecules with potential antiviral activity, which would hamper virus development. Our ligand-based screen yielded 370 compounds among the 6733-compound library, having normalized therapeutic activity value over the cutoff of 0.75. These 370 compounds were docked to SARS-CoV-2 M^{pro} and the top-50 scoring complexes were subjected to short 10 ns MD simulations. The MD simulations were followed by MM/GBSA calculations and the 10-top complexes with best average MM/GBSA scores were simulated for 100 ns and average MM/GBSA scores were calculated from their trajectories. End-point energy

Table 2. Docking scores of top-50 compounds at the M^{pro} binding site. These compounds were initially used in short (10 ns) MD simulations. Table also shows average MM/GBSA scores of these compounds from derived 100-trajectories throughout the simulations. Prediction of antiviral therapeutic activity for the selected hit molecules using MetaCore/MetaDrug was also reported in the table. Values in parenthesis – Tanimoto prioritization (TP) – indicates similarity of the analyzed structure to the most similar compound in the training set.

Compound name	Glide/SP docking score (kcal/mol)	Viral (TP)	10 ns	
			MM/GBSA (kcal/mol)	SD
Ibutamoren	-7.27	0.85 (49.84)	-80.07	7.34
Cefuroxime pivoxetil	-7.42	0.79 (33.60)	-74.63	7.88
Cefuroxime axetil	-7.60	0.79 (33.27)	-63.80	5.62
Ambamustine	-7.23	0.79 (58.30)	-61.89	9.00
Montirelin	-7.47	0.75 (54.38)	-59.39	3.60
Atevirdine	-6.35	0.75 (100.00)	-58.09	4.82
Ritonavir	-6.37	0.79 (100.00)	-54.38	11.18
Cilostamide	-6.45	0.77 (39.83)	-53.68	4.80
Amlodipine	-6.60	0.78 (34.10)	-53.63	4.63
Tafenoquine	-6.66	0.83 (40.28)	-53.40	4.98
Regadenoson	-6.47	0.88 (71.08)	-52.93	7.22
Opanixilum	-6.70	0.77 (48.40)	-51.07	4.45
Cefsumide	-6.98	0.80 (35.26)	-49.70	3.26
Cephaloglycin	-6.47	0.79 (38.26)	-48.96	7.75
Cefdinir	-6.44	0.75 (35.16)	-48.30	4.74
Triciribine	-6.39	0.91 (70.24)	-48.20	5.17
Piritrexim	-6.41	0.81 (37.67)	-47.16	5.65
Acadesine	-6.63	0.98 (60.38)	-47.12	3.95
Glibutimine	-6.41	0.80 (34.67)	-44.01	9.47
Loxoribine	-6.80	0.89 (64.73)	-42.87	5.89
Decitabine	-6.59	0.94 (72.83)	-42.46	5.70
Amdoxovir	-6.60	0.95 (100.00)	-40.80	5.80
Acrinol	-6.80	0.86 (34.88)	-40.44	6.46
Fludarabine	-6.36	0.91 (78.16)	-40.28	5.55
Tiamiprine	-6.84	0.79 (46.23)	-39.09	4.09
Penciclovir	-6.45	0.99 (100.00)	-38.81	4.82
Sulfacitine	-6.39	0.76 (40.00)	-36.94	5.66
Tiazofurine	-6.65	0.89 (37.20)	-36.46	6.67
Ampyrimine phosphate	-6.49	0.84 (38.79)	-36.08	3.29
Edoxudine	-6.81	0.99 (100.00)	-35.99	5.73

Table 2. (Continued).				
Compound name	Glide/SP docking score (kcal/mol)	Viral (TP)	10 ns	
			MM/GBSA (kcal/mol)	SD
Mitozolomide	-6.54	0.82 (33.33)	-33.68	9.73
Ancitabine	-6.42	0.95 (52.08)	-33.24	8.14
Zidovudine	-6.40	0.99 (100.00)	-32.65	4.48
Nelarabine	-6.38	0.95 (75.00)	-32.52	5.69
Entecavir	-6.86	0.99 (100.00)	-30.53	7.43
Inosine	-6.43	0.90 (87.50)	-30.51	6.10
Mitomycin	-7.40	0.85 (35.99)	-30.26	7.36
Clofarabine	-7.25	0.93 (87.45)	-29.92	13.01
Ly 163502	-6.46	0.85 (47.51)	-29.78	3.66
Gemcitabine	-6.38	0.99 (86.50)	-28.71	8.21
Mizoribine	-6.39	0.98 (55.80)	-26.26	5.26
Temodar	-6.61	0.80 (34.93)	-23.88	9.46
Navuridine	-6.38	0.99 (91.74)	-21.89	5.10
Ribavirin	-6.59	0.89 (100.00)	-20.08	13.37
Dametralast	-6.66	0.83 (37.91)	-17.46	5.51
6-Methoxy-1h-Purin-2-Ylamine	-6.51	0.80 (53.89)	-13.49	6.45

calculations from MD simulations revealed Cefuroxime pivoxetil, second-generation cephalosporin antibiotic, as being a considerable compound for drug repurposing against the SARS-CoV-2 M^{Pro}.

Acknowledgment

This study was supported by the TÜBİTAK 2247-C STAR program. This study was also funded by Scientific

Research Projects Commission of Bahçeşehir University. Project number: BAU.BAP.2020.01.

Conflict of interest

The authors declare that there is not any conflict of interest.

References

- Ahmed MZ, Zia Q, Haque A, Alqahtani AS, Almarfadi OM et al. (2021). Aminoglycosides as potential inhibitors of SARS-CoV-2 main protease: an in silico drug repurposing study on FDA-approved antiviral and anti-infection agents. *Journal of Infection and Public Health* 14 (5): 611-619. doi: 10.1016/j.jiph.2021.01.016
- Akhon BA, Tiwari H, Nargotra A (2019). In silico drug design methods for drug repurposing. In: Roy K (editor). *In Silico Drug Design*. Cambridge, MA, USA: Academic Press, pp. 47-84.
- Behnam MAM (2021). Protein structural heterogeneity: a hypothesis for the basis of proteolytic recognition by the main protease of SARS-CoV and SARS-CoV-2. *Biochimie* 182: 177-184. doi: 10.1016/j.biochi.2021.01.010
- Chen Y, Liu Q, Guo D (2020). Emerging coronaviruses: genome structure, replication, and pathogenesis. *Journal of Medical Virology* 92 (4): 418-423. doi: 10.1002/jmv.25681
- Dalerba P, Levin B, Thompson JL (2020). A trial of lopinavir-ritonavir in Covid-19. *The New England Journal of Medicine* 382 (21).

- Dogan B, Durdagi S (2020). Drug re-positioning studies for novel HIV-1 inhibitors using binary QSAR models and multi-target-driven *in silico* studies. *Molecular Informatics* 40 (2000012): 1-15. doi: 10.1002/minf.202000012
- Dong L, Tian J, He S, Zhu C, Wang J et al. (2020). Possible vertical transmission of SARS-CoV-2 from an infected mother to her newborn. *JAMA* 323 (18): 1846-1848. doi: 10.1001/jama.2020.4621
- Durdağı S (2020). Virtual drug repurposing study against SARS-CoV-2 TMPRSS2 target. *Turkish Journal of Biology* 44: 185-191.
- Durdagi S, Aksoydan B, Dogan B, Sahin K, Shahraki A (2020). Screening of clinically approved and investigation drugs as potential inhibitors of COVID-19 main protease: a virtual drug repurposing study. *ChemRxiv* 2020. doi: 10.26434/chemrxiv.12032712.v1
- Erben Y, Franco-Mesa C, Gloviczki P, Stone W, Quinones-Hinojoas A et al. (2021). Deep vein thrombosis and pulmonary embolism among hospitalized coronavirus disease 2019-positive patients predicted for higher mortality and prolonged intensive care unit and hospital stays in a multisite healthcare system. *Journal of Vascular Surgery: Venous and Lymphatic Disorders*. doi: 10.1016/j.jvsv.2021.03.009
- Ghosh AK, Brindisi M, Shahabi D, Chapman ME, Mesecar AD (2020). Drug development and medicinal chemistry efforts toward SARS-coronavirus and Covid-19 therapeutics. *ChemMedChem* 15 (11): 907-932. doi: 10.1002/cmdc.202000223
- Guedes IA, Costa LSC, Dos Santos KB, Karl ALM, Rocha GK et al. (2021). Drug design and repurposing with DockThor-VS web server focusing on SARS-CoV-2 therapeutic targets and their non-synonym variants. *Scientific Reports* 11 (1): 5543. doi: 10.1038/s41598-021-84700-0
- Han YJ, Lee KH, Yoon S, Nam SW, Ryu S et al. (2021). Treatment of severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and coronavirus disease 2019 (COVID-19): a systematic review of *in vitro*, *in vivo*, and clinical trials. *Theranostics* 11 (3): 1207-1231. doi: 10.7150/thno.48342
- Haston JC, Hwang J, Tan KR (2019). Guidance for using tafenoquine for prevention and antirelapse therapy for malaria — United States, 2019. *Morbidity and Mortality Weekly Report* 68 (46): 1062-1068. doi: 10.15585/mmwr.mm6846a4
- Hou T, Wang J, Li Y, Wang W (2011). Assessing the performance of the MM/PBSA and MM/GBSA methods. 1. The accuracy of binding free energy calculations based on molecular dynamics simulations. *Journal of Chemical Information and Modeling* 51: 69-82.
- Horby PW, Mafham M, Bell JL, Linsell L, Staplin N et al. (2020). Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. *The Lancet* 396 (10259): 1345-1352.
- Kanan D, Kanan T, Dogan B, Orhan MD, Avsar T (2021). An integrated *in silico* approach and *in vitro* study for the discovery of small-molecule USP7 inhibitors as potential cancer therapies. *ChemMedChem* 16 (3): 555-567. doi: 10.1002/cmdc.202000675
- Kirtipal N, Bharadwaj S, Kang SG (2020). From SARS to SARS-CoV-2, insights on structure, pathogenicity and immunity aspects of pandemic human coronaviruses. *Infection, Genetics and Evolution* 85: 104502. doi: 10.1016/j.meegid.2020.104502
- Miller BR, McGee TD, Swails JM, Homeyer N, Gohlke H et al. (2012). MMPBSA.py: an efficient program for end-state free energy calculations. *Journal of Chemical Theory and Computation* 8: 3314-3321.
- Molavi Z, Razi S, Mirmotalebisohi SA, Adibi A, Sameni M et al. (2021). Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach. *Biomedicine & Pharmacotherapy* 138: 111544. doi: 10.1016/j.biopha.2021.111544
- Potere N, Valeriani E, Candeloro M, Tana M, Porreca E et al. (2020). Acute complications and mortality in hospitalized patients with coronavirus disease 2019: a systematic review and meta-analysis. *Critical Care* 24 (1): 389. doi: 10.1186/s13054-020-03022-1
- Reichman RC, Morse GD, Demeter LM, Resnick L, Bassiakos Y et al. (1995). Phase I study of atevirdine, a nonnucleoside reverse transcriptase inhibitor, in combination with zidovudine for human immunodeficiency virus type 1 infection. *Journal of Infectious Diseases* 171 (2): 297-304.
- Rothan HA, Teoh TC (2021). Cell-based high-throughput screening protocol for discovering antiviral inhibitors against SARS-CoV-2 main protease (3CLpro). *Molecular Biotechnology* 63 (3): 240-248. doi: 10.1007/s12033-021-00299-7
- Ruano-Gallego D, García-Villadangos M, Moreno-Paz M, Gómez-Elvira J, Postigo M et al. (2021). A multiplex antigen microarray for simultaneous IgG and IgM detection against SARS-CoV-2 reveals higher seroprevalence than reported. *Microbial Biotechnology* 14 (3): 1228-1236. doi: 10.1111/1751-7915.13801
- Scott LJ, Ormrod D, Goa KL (2001). Cefuroxime axetil: an updated review of its use in the management of bacterial infections. *Drugs* 61 (10): 1455-1500. doi: 10.2165/00003495-200161100-00008
- Shitrit A, Zaidman D, Kalid O, Bloch I, Doron D et al. (2020). Conserved interactions required for inhibition of the main protease of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). *Scientific Reports* 10 (1): 20808. doi: 10.1038/s41598-020-77794-5
- Silvestrini L, Belhaj N, Comez L, Gerelli Y, Lauria A et al. (2021). The dimer-monomer equilibrium of SARS-CoV-2 main protease is affected by small molecule inhibitors. *Scientific Reports* 11 (1): 9283. doi: 10.1038/s41598-021-88630-9

- Singh R, Gautam A, Chandel S, Sharma V, Ghosh A et al. (2021). Computational screening of FDA approved drugs of fungal origin that may interfere with SARS-CoV-2 spike protein activation, viral RNA replication, and post-translational modification: a multiple target approach. In *Silico Pharmacology* 9 (1): 27. doi: 10.1007/s40203-021-00089-8
- Solaimanzadeh I (2020). Nifedipine and Amlodipine Are Associated with Improved Mortality and Decreased Risk for Intubation and Mechanical Ventilation in Elderly Patients Hospitalized for COVID-19. *Cureus* 12 (5): e8069. doi: 10.7759/cureus.8069
- Sugimoto T, Hayashi T, Okita A, Morino A (1996). Pharmacokinetics of the new thyrotropin releasing hormone analogue montirelin hydrate. 3rd communication: identification of metabolites in rat urine. *Arzneimittel-forschung* 46 (2): 127-133.
- Tutumlu G, Dogan B, Avsar T, Orhan MD, Calis S et al. (2020). Integrating ligand and target-driven based virtual screening approaches with in vitro human cell line models and time-resolved fluorescence resonance energy transfer assay to identify novel hit compounds against BCL-2. *Frontiers in Chemistry* 8: 167. doi: 10.3389/fchem.2020.00167
- Wu Y, Ho W, Huang Y, Jin D-Y, Li S et al. (2020). SARS-CoV-2 is an appropriate name for the new coronavirus. *The Lancet* 395 (10228): 949-950. doi: 10.1016/S0140-6736(20)30557-2
- Yoon Y-S, Jang Y, Hoenen T, Shin H, Lee Y et al. (2020). Antiviral activity of sertindole, raloxifene and ibutamoren against transcription and replication-competent Ebola virus-like particles. *Journal of Biochemistry and Molecular Biology* 53 (3): 166.
- Yoshino R, Yasuo N, Sekijima M (2020). Identification of key interactions between SARS-CoV-2 main protease and inhibitor drug candidates. *Scientific Reports* 10 (1): 12493. doi: 10.1038/s41598-020-69337-9
- Zhang L, Lin D, Sun X, Curth U, Drosten C et al. (2020). Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α -ketoamide inhibitors. *Science* 368 (6489): 409-412. doi: 10.1126/science.abb3405

Supplementary materials

Table S1. MetaCore/MetaDrug results of therapeutic activity prediction for the screened compounds which have normalized activity value of 0.75 or higher along with Glide/SP docking scores.

Compound name	Glide/SP docking score (kcal/mol)	Antiviral (TP)
Cefuroxime axetil	-7.60	0.79 (33.27)
Montirelin	-7.47	0.75 (54.38)
Cefuroxime pivoxetil	-7.42	0.79 (33.60)
Mitomycin	-7.40	0.85 (35.99)
Fluorocytidine	-7.35	0.95 (52.00)
Ibutamoren	-7.27	0.85 (49.84)
Clofarabine	-7.25	0.93 (87.45)
Ambamustine	-7.23	0.79 (58.30)
Cefsumide	-6.98	0.80 (35.26)
Entecavir	-6.86	0.99 (100.00)
Tiamiprine	-6.84	0.79 (46.23)
Edoxudine	-6.81	0.99 (100.00)
Loxoribine	-6.80	0.89 (64.73)
Acrinol	-6.80	0.86 (34.88)
Opanixilum	-6.70	0.77 (48.40)
Dametralast	-6.66	0.83 (37.91)
Tafenoquine	-6.66	0.83 (40.28)
Tiazofurine	-6.65	0.89 (37.20)
Acadesine	-6.63	0.98 (60.38)
Temodar	-6.61	0.80 (34.93)
Amdoxovir	-6.60	0.95 (100.00)
Amlodipine	-6.60	0.78 (34.10)
Decitabine	-6.59	0.94 (72.83)
Ribavirin	-6.59	0.89 (100.00)
Clevudine	-6.57	0.98 (100.00)
Floxuridine	-6.56	0.99 (100.00)
Mitozolomide	-6.54	0.82 (33.33)
6-Methoxy-1h-purin-2-ylamine	-6.51	0.80 (53.89)
Ampyrimine phosphate	-6.49	0.84 (38.79)
Regadenoson	-6.47	0.88 (71.08)
Cephaloglycin	-6.47	0.79 (38.26)
Ly 163502	-6.46	0.85 (47.51)
Penciclovir	-6.45	0.99 (100.00)
Cilostamidum	-6.45	0.77 (39.83)
Cefdinir	-6.44	0.75 (35.16)
Inosine	-6.43	0.90 (87.50)

Compound name	Glide/SP docking score (kcal/mol)	Antiviral (TP)
Ancitabine	-6.42	0.95 (52.08)
Omaciclovir	-6.42	0.99 (93.33)
Piritrexim	-6.41	0.81 (37.67)
Glibutimine	-6.41	0.80 (34.67)
Zidovudine	-6.40	0.99 (100.00)
Triciribine	-6.39	0.91 (70.24)
Mizoribine	-6.39	0.98 (55.80)
Sulfacitine	-6.39	0.76 (40.00)
Navuridine	-6.38	0.99 (91.74)
Gemcitabine	-6.38	0.99 (86.50)
Nelarabine	-6.38	0.95 (75.00)
Ritonavir	-6.37	0.79 (100.00)
Fludarabine	-6.36	0.91 (78.16)
Atevirdine	-6.35	0.75 (100.00)
Cladribine	-6.33	0.93 (87.27)
Lobucavir	-6.32	0.99 (84.15)
Leminoprazole	-6.32	0.76 (32.70)
Netivudine	-6.31	0.99 (100.00)
Peldesine	-6.31	0.76 (45.45)
Vidarabine_1	-6.30	0.91 (85.71)
Isatoribine	-6.30	0.98 (52.48)
Arabinosylthymine	-6.28	0.98 (93.27)
Telbivudine	-6.28	0.99 (100.00)
Alovudine	-6.27	0.99 (100.00)
Azacitidine	-6.26	0.94 (69.39)
Batracylin	-6.26	0.76 (34.89)
Buciclovir	-6.25	0.99 (100.00)
Tanaprogetum	-6.24	0.87 (36.88)
Sapropterin	-6.23	0.81 (49.21)
Rabeprazole	-6.22	0.79 (29.94)
Uk-52,046	-6.20	0.80 (47.79)
Etryptamine	-6.20	0.77 (36.88)
Azepexolum	-6.17	0.84 (24.77)
Binodenoson	-6.16	0.78 (80.00)
7-Amino-cephalosporanic acid	-6.16	0.75 (31.33)
Azelnidipine	-6.15	0.75 (34.26)
Milacainide	-6.15	0.76 (44.91)
Mioflazinum	-6.15	0.75 (46.93)
Capromorelin	-6.14	0.75 (50.59)
Dacopafant	-6.14	0.78 (31.79)
Monophosphothiamine	-6.14	0.85 (28.72)

Compound name	Glide/SP docking score (kcal/mol)	Antiviral (TP)
Cycotiamine	-6.13	0.83 (29.58)
Protionamidum	-6.11	0.77 (29.88)
Emtricitabine	-6.11	0.99 (62.50)
Cytarabine	-6.10	0.99 (92.97)
Amprolio	-6.06	0.88 (40.11)
Cefadroxil	-6.06	0.76 (36.90)
Triamterene	-6.06	0.84 (40.16)
Cefoxitin	-6.05	0.79 (34.69)
Cipamfylline	-6.05	0.91 (100.00)
Aditoprim	-6.05	0.76 (43.11)
Enviradene	-6.04	0.89 (100.00)
Lansoprazole	-6.04	0.78 (29.58)
Evandamine	-6.03	0.83 (29.28)
Euprocin	-6.03	0.75 (49.44)
Tioguanine	-6.02	0.81 (44.52)
Cefradine	-6.01	0.77 (36.09)
Fialuridine	-6.01	0.98 (100.00)
Etricitat	-6.00	0.80 (35.21)
Adenosine_1	-6.00	0.91 (83.88)
(+/-)-5-(.Alpha.-imidazol-1-ylbenzyl)-2-methylbenzimidazole	-6.00	0.76 (41.90)
Raluridine	-5.99	0.99 (100.00)
Resiquimod	-5.99	0.83 (70.98)
Chloroethyl thiamine	-5.98	0.84 (30.00)
Ethyl lofazepate	-5.97	0.88 (38.11)
Cifostodine	-5.96	0.99 (69.64)
Cocarboxylase	-5.95	0.85 (33.16)
Airomate	-5.93	0.87 (38.70)
Lamivudine_1	-5.93	0.76 (100.00)
Alprazolam	-5.93	0.75 (31.71)
Ecenofloxacin	-5.93	0.80 (38.51)
Rocepaft	-5.93	0.76 (34.89)
Ethyl dirazepate	-5.92	0.88 (31.20)
Zalcitabine	-5.92	0.99 (100.00)
N-cyclopropylmelamine	-5.92	0.76 (24.22)
Diaveridine	-5.91	0.75 (47.48)
Zaleplon	-5.91	0.83 (34.33)
Torcitabine	-5.90	0.99 (100.00)
Girodazole	-5.90	0.77 (30.17)
Oseltamivir	-5.90	0.81 (47.24)
Famciclovir	-5.89	0.99 (100.00)

Compound name	Glide/SP docking score (kcal/mol)	Antiviral (TP)
Cefetamet	-5.88	0.76 (35.04)
Tomeglovir	-5.87	0.82 (100.00)
Acetiamine	-5.87	0.82 (29.03)
Cefoxazole	-5.87	0.77 (38.05)
Brivudine	-5.87	0.99 (100.00)
Arpocox	-5.87	0.77 (56.63)
Emorfazone	-5.87	0.82 (34.38)
Pirolate	-5.87	0.75 (38.36)
Trimetrexate	-5.87	0.88 (41.02)
Enecadinum	-5.87	0.80 (33.33)
N acetyl d galactosamin	-5.86	0.77 (69.14)
Nolatrexed	-5.86	0.79 (35.38)
Azalanstat	-5.85	0.75 (37.96)
Abacavir	-5.85	0.94 (100.00)
Pancopride	-5.85	0.80 (48.21)
Sr 57227a	-5.85	0.75 (38.46)
Cns-1102	-5.85	0.86 (30.51)
Colfenamate	-5.85	0.77 (34.12)
Epiroprim	-5.84	0.87 (39.51)
Isoprazone	-5.84	0.75 (34.39)
Sorivudine	-5.84	0.99 (100.00)
Esaflloxacin	-5.84	0.75 (36.65)
Lenampicillin_1	-5.83	0.76 (41.23)
Ganciclovir	-5.82	0.98 (100.00)
Lemildipine	-5.82	0.81 (35.02)
Metioprim	-5.82	0.78 (39.19)
2-Amino-6-chloropurine	-5.82	0.79 (44.37)
Mepacrine	-5.82	0.75 (45.41)
Ibicitabine	-5.81	0.99 (100.00)
Valganciclovir	-5.81	0.96 (78.50)
Triazolam	-5.81	0.75 (31.10)
Tezacitabine	-5.81	0.99 (77.13)
Nsc-98700	-5.80	0.95 (87.75)
Trimethoprim	-5.80	0.75 (45.83)
Tiquinamide	-5.80	0.77 (37.19)
Epervudine	-5.79	0.99 (100.00)
Nsc-4911	-5.76	0.81 (82.33)
Fradafiban	-5.76	0.75 (47.96)
Maribavir	-5.75	0.91 (100.00)
Vintiamol	-5.75	0.78 (32.67)
Cefalexin	-5.74	0.77 (37.85)
Amoxicillin	-5.74	0.78 (45.24)

Compound name	Glide/SP docking score (kcal/mol)	Antiviral (TP)
4-(4-Fluorobenzoyl) pyridinium p-toluenesulfonate	-5.74	0.82 (42.35)
4-fluorobenzyl-1h-benzimidazol-2-ylamine		
Xenazotic acid	-5.73	0.86 (100.00)
4-Nitrobenzyl 6-(2-phenoxyacetamido) penicillanate 1-oxide	-5.73	0.77 (38.10)
Lodenosine	-5.73	0.95 (100.00)
Clavulanic acid	-5.73	0.77 (35.83)
Ethoxazolamide	-5.72	0.76 (25.85)
Sulfadimethoxine	-5.72	0.75 (38.96)
Zaltidine	-5.72	0.83 (34.19)
Valaciclovir	-5.71	0.96 (78.42)
6-Amino-5-formamido-1,3-dimethyluracil	-5.71	0.75 (38.50)
Lenampicillin	-5.70	0.76 (41.23)
Adenosine	-5.70	0.95 (100.00)
Spirgetine	-5.69	0.76 (36.67)
Bropiramine	-5.69	0.75 (30.84)
Trifluridine	-5.68	0.99 (100.00)
Talviraline	-5.68	0.80 (100.00)
Tenatoprazole	-5.65	0.76 (31.70)
Aciclovir	-5.65	0.98 (100.00)
Disuprazole	-5.64	0.79 (31.09)
Tetroxoprim	-5.64	0.75 (42.14)
Adenosine cyclic 3',5'-phosphate	-5.64	0.91 (85.71)
Ronidazole	-5.64	0.83 (27.08)
Fenacetinol	-5.64	0.75 (50.85)
Iclaprim	-5.64	0.75 (36.51)
Stavudine	-5.63	0.97 (100.00)
Brecaevir	-5.62	0.79 (100.00)
Etravirine	-5.62	0.92 (100.00)
Stibamini glucosidum	-5.61	0.76 (39.56)
Cefpodoxime	-5.60	0.81 (35.07)
B 4, vitamini	-5.60	0.76 (47.26)
Benzyl (1-carbamoyl-2-hydroxypropyl) carbamate	-5.60	0.83 (38.83)
Tegafur	-5.60	0.88 (81.91)
4-Amino-neu5ac2en	-5.59	0.92 (89.00)
Opaviraline	-5.59	0.83 (100.00)
Sc-33643	-5.58	0.94 (36.68)

Compound name	Glide/SP docking score (kcal/mol)	Antiviral (TP)
Mosapride	-5.57	0.85 (41.11)
Didanosine	-5.57	0.93 (100.00)
Pyrimidine, 4-methoxy-2-(5-methoxy-3-methyl-1h-pyrazol-1-yl)-6-methyl-	-5.55	0.84 (32.63)
Epetirimod esylate	-5.55	0.93 (82.76)
Imanixil	-5.54	0.79 (47.29)
Emivirine	-5.54	0.93 (100.00)
Fursultiamine	-5.54	0.77 (28.38)
Ormetoprim	-5.53	0.79 (45.21)
Pleconaril	-5.53	0.83 (100.00)
Idoxuridine	-5.52	0.99 (77.63)
Cefuroxime pivoxetil	-5.51	0.80 (33.33)
Lirexapride	-5.51	0.78 (45.61)
Pyrazinamidum	-5.51	0.75 (25.12)
Darunavir	-5.51	0.84 (87.90)
Lamotrigine	-5.50	0.76 (51.87)
Tolonium	-5.50	0.76 (25.00)
Amprenavir	-5.49	0.96 (100.00)
Imexon	-5.47	0.79 (22.29)
Adefovir	-5.46	0.96 (100.00)
Isotiquimide	-5.45	0.78 (37.37)
Epinalastine	-5.45	0.81 (36.59)
Quinazolin	-5.45	0.80 (53.48)
Lomeguatribum	-5.45	0.91 (40.91)
1-(α -D-arabinofuranosyl) pyrimidine-2,4(1h,3h)-dione	-5.42	0.97 (84.30)
Roxifiban	-5.42	0.75 (47.06)
Troxacitabine	-5.42	0.99 (61.34)
(S)-tetrahydro-3-furyl (m-(3-(3-methoxy-4-(5-oxazolyl) phenyl)ureido)benzyl) carbamate	-5.41	0.77 (100.00)
Pentisomide	-5.41	0.75 (53.08)
6-Chloro-2-ethylamino-4-methyl-4-phenyl-4h-3,1-benzoxazine hydrochloride	-5.40	0.81 (42.80)
Lanocanazole	-5.40	0.75 (28.81)
Aditeren	-5.40	0.76 (44.94)
Pramipexole	-5.38	0.82 (32.40)
Minoxidil	-5.38	0.76 (37.57)
Saprisartan	-5.36	0.84 (32.37)
Loviride	-5.36	0.88 (100.00)
Sch-42495	-5.36	0.80 (53.62)

Compound name	Glide/SP docking score (kcal/mol)	Antiviral (TP)
Alfuzosin	-5.35	0.79 (53.88)
Bamnidazole	-5.34	0.84 (33.33)
Azanidazole	-5.34	0.82 (26.15)
Brodimoprim	-5.33	0.78 (43.06)
4H-thiazolo(4,5-d) azepin-2-amine, 5,6,7,8-tetrahydro-6-(2-propenyl)-, dihydrochloride	-5.33	0.82 (27.86)
Cefixime	-5.32	0.84 (35.11)
Sulfacecole	-5.31	0.78 (47.37)
Guanethidine	-5.30	0.76 (44.44)
Orbutopril	-5.29	0.77 (64.14)
Darodipine	-5.29	0.77 (30.72)
Adefovir_1	-5.27	0.95 (100.00)
Nepicastat	-5.27	0.77 (36.40)
Ampicillin	-5.27	0.79 (46.81)
Carbubarb	-5.26	0.81 (68.32)
Freselestat	-5.26	0.78 (32.02)
Vardenafil	-5.25	0.76 (36.72)
Benzoic acid, 4-(acetylamino)-2-ethoxy-, methyl ester	-5.25	0.77 (51.72)
imiquimod	-5.24	0.95 (100.00)
4-Amino-2-chloro-6,7-dimethoxyquinazoline	-5.24	0.78 (46.51)
Batanopride	-5.24	0.76 (44.71)
Vidarabine	-5.23	0.95 (100.00)
5-Methyl-2-(2-nitroanilino) thiophene-3-carbonitrile	-5.22	0.79 (28.08)
Enviroxime	-5.22	0.90 (100.00)
Amanozinum	-5.22	0.77 (43.97)
Cinitapride	-5.21	0.84 (41.71)
Diphenylguanidine	-5.20	0.77 (31.31)
Zanamivir	-5.19	0.97 (84.58)
2-Cyano-3-morpholinoacrylamide	-5.19	0.79 (31.82)
Cefdaloximum	-5.18	0.81 (35.16)
Febuxostat	-5.18	0.81 (35.59)
Guabenxan	-5.18	0.75 (46.26)
Palatrigine hydrochloride	-5.18	0.81 (48.83)
Fiacitabine	-5.18	0.99 (100.00)
Lamivudine	-5.16	0.99 (57.00)
Fludarabine_1	-5.16	0.95 (89.87)

Compound name	Glide/SP docking score (kcal/mol)	Antiviral (TP)
4,6-Diamino-1-(p-chlorophenyl)-1,2-dihydro-2,2-dimethyl-s-triazine salt of 4,4'-methylene-bis(3-hydroxy-2-naphthoic acid)	-5.15	0.78 (26.11)
Metahexamide	-5.15	0.78 (39.46)
Epicillin	-5.15	0.79 (41.42)
Luliconazole	-5.15	0.75 (28.99)
Besipirdine	-5.14	0.76 (34.97)
Tolycaine	-5.14	0.75 (42.86)
Ethyl 2-(2-amino-1,3-thiazol-4-yl)-2-hydroxyiminoacetate	-5.13	0.80 (25.07)
2,6-Pyridinediamine, 3-(phenylazo)-, monohydrochloride	-5.12	0.75 (27.81)
Mapinastine	-5.11	0.75 (43.56)
5'-Inosinic acid, homopolymer, complex with 5'-cytidylic acid homopolymer (1:1)	-5.08	0.86 (75.60)
Prosultiamine	-5.06	0.81 (29.66)
Antramycin	-5.06	0.79 (38.27)
Amisulpride	-5.05	0.79 (43.70)
Hoe 757	-5.05	0.77 (40.95)
Chlorazanol	-5.04	0.77 (40.31)
Desciclovir	-5.04	0.93 (100.00)
Primaquine	-5.03	0.77 (45.41)
Baquiloprim	-5.03	0.80 (45.09)
Ubenimex	-5.03	0.79 (66.44)
Alepride	-5.02	0.84 (43.69)
Dazopride	-5.01	0.81 (44.91)
Sildenafil	-5.01	0.76 (39.01)
Ethyl (z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino) acetate	-5.01	0.82 (24.57)
Sulfacloamide	-4.99	0.78 (38.26)
Quinocide	-4.98	0.79 (45.16)
Spirotriazine hydrochloride	-4.98	0.85 (30.30)
Sulfaperin	-4.97	0.77 (38.42)
Sulfalene	-4.96	0.76 (39.91)
Furterenum	-4.96	0.88 (37.91)
3H-1,2-dithiole-3-thione, 4-methyl-5-pyrazinyl-	-4.94	0.75 (100.00)
Taprizosinum	-4.94	0.84 (40.96)
Rociclovir	-4.94	0.99 (100.00)

Compound name	Glide/SP docking score (kcal/mol)	Antiviral (TP)
Xylamidine	-4.93	0.78 (47.77)
Disoxaril	-4.93	0.89 (100.00)
Percodan	-4.92	0.77 (54.21)
Alamifovir	-4.91	0.85 (95.42)
Dimoxyline	-4.91	0.76 (39.75)
Romazarit	-4.91	0.77 (31.22)
3-(Cyanoimino)-3-piperidinopropionitrile	-4.90	0.78 (28.95)
Naminidil	-4.87	0.87 (30.56)
Fosamprenavir	-4.87	0.96 (100.00)
Pyrimitate	-4.87	0.76 (29.91)
Sk&f 9267	-4.87	0.76 (28.22)
Midamor	-4.86	0.77 (29.50)
Tenofovir	-4.84	0.92 (100.00)
Dacarbazine	-4.83	0.76 (26.80)
Sulfamerazine sodium	-4.82	0.75 (39.83)
Pyrimethamine	-4.81	0.81 (55.81)
Ci 994	-4.81	0.76 (68.22)
Santoquin	-4.80	0.75 (35.16)
Phenacainum	-4.80	0.78 (34.51)
Bm 41332	-4.78	0.77 (31.28)
Moroxydine	-4.78	0.92 (58.44)
Erlotinib	-4.77	0.77 (53.78)
Repaglinide	-4.74	0.78 (47.08)
Sulfasymazine	-4.74	0.85 (37.31)
Timegadinum	-4.73	0.76 (32.52)
Ontazolast	-4.73	0.77 (31.58)
Sulfametomidine	-4.72	0.80 (37.72)
Tivirapine	-4.69	0.79 (79.13)
Guanclotine	-4.67	0.76 (30.77)
Etocarlidum	-4.66	0.76 (43.36)
Apraclonidine	-4.64	0.78 (28.14)
Cetotiamine	-4.63	0.77 (29.25)
Midaxifylline	-4.63	0.76 (50.60)
Ioxotrizoic acid	-4.62	0.77 (36.69)
Poly c	-4.61	0.95 (77.83)
Tromantadine	-4.59	0.85 (100.00)
Sulfamerazine_1	-4.58	0.84 (37.76)
Bw 1970	-4.57	0.76 (63.35)
Sulfabromomethazine sodium	-4.55	0.82 (35.55)
Lapudrine	-4.55	0.85 (28.42)

Compound name	Glide/SP docking score (kcal/mol)	Antiviral (TP)
8-Chloroadenosine 3',5'-monophosphate	-4.54	0.93 (73.12)
Isamoxol	-4.52	0.86 (27.11)
Sulfaguanole	-4.52	0.79 (32.09)
Zaprinast	-4.51	0.78 (37.80)
Sulfametoxydiazine	-4.48	0.76 (37.76)
Bentiamine	-4.46	0.82 (29.71)
Aminoquinol	-4.43	0.75 (36.50)
Pinacidil	-4.37	0.84 (28.57)
Lauroguadinum	-4.35	0.85 (42.86)
1-(4-Chlorophenyl)-5-isopropyl-biguanide hydrochloride	-4.30	0.85 (28.83)
Terofenamate	-4.28	0.78 (39.80)
Eclazolast	-4.26	0.83 (24.14)
Trapenaine	-4.21	0.75 (46.60)
Sopromidinum	-4.18	0.79 (30.45)
Sulfisomidine	-4.15	0.84 (41.35)
Benoxafos	-4.10	0.85 (23.32)
Adenosine triphosphate	-4.07	0.95 (80.95)
Tiamenidine	-4.06	0.75 (22.43)
Carbante	-4.06	0.82 (41.61)
N'-a-(tert-butyloxycarbonyl)-n'-omega-nitro-l-arginine	-4.04	0.76 (38.51)
Tigemonam	-4.01	0.85 (33.25)
Benphothiamine	-3.91	0.79 (31.37)
Nisobamate	-3.83	0.77 (32.21)
Silver sulfadiazine	-3.82	0.75 (39.83)
Sulfamerazine	-3.82	0.84 (37.56)
Atolide	-3.70	0.77 (58.40)
Carisoprodol	-3.69	0.77 (32.65)
Carbocloralum	-3.41	0.76 (18.88)
Cidofovir	-3.39	0.93 (100.00)
Lorbamate	-3.33	0.84 (33.01)
Maraviroc	-3.30	0.79 (100.00)
Fuladectin gapromidine	-2.91	0.80 (41.04)
Amidantel	-2.66	0.76 (33.80)

Glide/SP Docking Scores of 370 Identified Compounds




Figure S1. Glide/SP docking scores of identified 374 compounds from 6733-compound library from the NPC database.




Figure S2. Protein backbone RMSD of selected top-10 compounds for 100 ns.




Figure S3. Lig Fit Prot RMSD of selected top-10 compounds for 100 ns.




Figure S4. (A) 3D representation of the Ibutamoren at binding site. The average frame from 100 ns trajectory was used. (B) 2D interaction diagram of Ibutamoren at M^{PRO} binding site with residues around 3 Å. (C) Time-dependent protein-ligand contact panel throughout 100 ns simulation. Top-panel shows total contacts, while bottom-panel shows formed/broken interaction between the protein and ligand.




Figure S5. (A) 3D representation of the Ateviridine at binding site. The average frame from 100 ns trajectory was used. (B) 2D interaction diagram of Ateviridine at M^{pro} binding site with residues around 3 Å. (C) Time-dependent protein-ligand contact panel throughout 100 ns simulation. Top-panel shows total contacts, while bottom-panel shows formed/broken interaction between the protein and ligand.




Figure S6. (A) 3D representation of the Ambamustine at binding site. The average frame from 100 ns trajectory was used. (B) 2D interaction diagram of Ambamustine at M^{pro} binding site with residues around 3 Å. (C) Time-dependent protein-ligand contact panel throughout 100 ns simulation. Top-panel shows total contacts, while bottom-panel shows formed/broken interaction between the protein and ligand.




Figure S7. (A) 3D representation of Cilostamide at binding site. The average frame from 100 ns trajectory was used. (B) 2D interaction diagram of Cilostamide at M^{PTO} binding site with residues around 3 Å. (C) Time-dependent protein-ligand contact panel throughout 100 ns simulation. Top-panel shows total contacts, while bottom-panel shows formed/broken interaction between the protein and ligand.






Figure S8. (A) 3D representation of the Tafenoquine at binding site. The average frame from 100 ns trajectory was used. (B) 2D interaction diagram of Tafenoquine at M^{pro} binding site with residues around 3 Å. (C) Time-dependent protein-ligand contact panel throughout 100 ns simulation. Top-panel shows total contacts, while bottom-panel shows formed/broken interaction between the protein and ligand.

A



B



C




Figure S9. (A) 3D representation of the Montirelin at binding site. The average frame from 100 ns trajectory was used. (B) 2D interaction diagram of Montirelin at M^{pro} binding site with residues around 3 Å. (C) Time-dependent protein-ligand contact panel throughout 100 ns simulation. Top-panel shows total contacts, while bottom-panel shows formed/broken interaction between the protein and ligand.




Figure S10. (A) 3D representation of the Ritonavir at binding site. The average frame from 100 ns trajectory was used. (B) 2D interaction diagram of Ritonavir at M^{pro} binding site with residues around 3 Å. (C) Time-dependent protein-ligand contact panel throughout 100 ns simulation. Top-panel shows total contacts, while bottom-panel shows formed/broken interaction between the protein and ligand.




Figure S11. (A) 3D representation of the Amlodipine at binding site. The average frame from 100 ns trajectory was used. (B) 2D interaction diagram of Amlodipine at M^{pro} binding site with residues around 3 Å. (C) Time-dependent protein-ligand contact panel throughout 100 ns simulation. Top-panel shows total contacts, while bottom-panel shows formed/broken interaction between the protein and ligand.




Figure S12. (A) 3D representation of the Cefuroxime Axetil at binding site. The average frame from 100 ns trajectory was used. (B) 2D interaction diagram of Cefuroxime Axetil at M^{pro} binding site with residues around 3 Å. (C) Time-dependent protein-ligand contact panel throughout 100 ns simulation. Top-panel shows total contacts, while bottom-panel shows formed/broken interaction between the protein and ligand.